Home | About Mosaic | News | Publications

Publications

Mosaic Laboratories has co-authored or been referenced in the following publications with pharmaceutical and biotechnology companies:

2010	Attenuon LLC and Mosaic Laboratories, LLC Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA and Mazar AP. An anti-urokinase receptor (uPAR) antibody (ATN-658) blocks prostate cancer invasion, migration, growth and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010 Oct;12(10):778-88	ARTICLE
2010	Proacta Inc. and Mosaic Laboratories, LLC (Referenced in Methods) Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010 Feb 15;70(4):1573-84.	ARTICLE
2009	Vertex Pharmaceuticals and Mosaic Laboratories, LLC Wang T, Duffy JP, Wang J, Halas S, Salituro FG, Pierce AC, Zuccola HJ, Black JR, Hogan JK, Jepson S, Shlyakter D, Mahajan S, Gu Y, Hoock T, Wood M, Furey BF, Frantz JD, Dauffenbach LM, Germann UA, Fan B, Namchuk M, Bennani YL, Ledeboer MW. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.	ARTICLE